Boston Scientific hits 52-week high

Boston Scientific

Boston Scientific (NYSE:BSX) shares hit a 52-week high 2 days ago and are flirting with another today, as investors react to strong 4th-quarter and 2012 results.

The Marlborough, Mass.-based medical device company’s stock hit $7.43 per share Jan. 29, the day it announced its financial numbers. Shares had fallen as low as $4.79 apiece during the last 52 weeks.

Today BSX shares hit that high again, trading at $7.43 each as of about 1:50 p.m., up 1.6%.

Boston Scientific posted 4th-quarter profits of $60 million, or 4¢ per share, on sales of $1.82 billion for the 3 months ended Dec. 31, 2012, representing a bottom-line slide of 43.9% and a sales decrease of 1.5% compared with the same period in 2011.

For full-year 2012, the company reported losses of $4.07 billion, or $2.89 per share, on sales of $7.25 billion. That’s a top-line slide of 4.9%.

Boston Scientific also said it’s expanding the streamlining effort it started in 2011, adding 1,000 layoffs to the 1,400 job cuts it’s already put in place. Aiming to pare pre-tax operating expenses by $100 million to $115 million annually by the end of the year, plus the $340 million to $375 million in savings it expects to reap from the 2011 initiative, Boston Scientific said it plans to let another 900 to 1,000 employees go.

Leerink Swann analyst Danielle Antalffy said the results indicate that Boston Scientific could be on a path to sustainable growth after several years in the wilderness.

"While one quarter doesn’t make a trend, we are certainly encouraged by what we believe are stable-to-improving market shares across most businesses and – in particular – within [implantable cardiac devices] and [drug-eluting stents]," Antalffy wrote in a note to investors this week. "But BSX will need to continue managing though markets where growth remains under pressure, with a recovery in procedure volumes still tenuous at best, and price declines likely to continue for the foreseeable future.

"In order for BSX stock to continue to outperform from here, we expect the company will need to successfully execute on: 1) recent and upcoming new product launches; and 2) execute on driving operating margins in-line with or better than management’s current expectation for a ~100 [basis point] decline over the next 12 months."

Stents and cardiac rhythm management devices, both bread-and-butter markets for Boston Scientific that accounted for 54.4% of its revenues during the quarter, have been in decline for the past few years. Sales for the company’s CRM business were off by 4% during Q4 and its interventional cardiology business was down 9%, CEO Michael Mahoney told analysts during a conference call this week.

"While we’re disappointed in our lack of growth, we believe that our U.S. DES share is stabilizing and we were able to grow international DES revenue mid-single digits," Mahoney said.

"[W]ith the upcoming launches of new products, along with the acquisition of BridgePoint Medical‘s suite of CTO devices, we expect to see continued improvement in this business over the course of 2013," added CFO Jeffrey Capello.

As for CRM, Mahoney said the slump seems to be ebbing.

"[W]e believe that the worldwide CRM market continued to show signs of stabilization during the quarter, declining to low to mid-single digits for the full year," he said.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply